|DB05202||Egaptivon pegol||Platelet aggregation, thrombosis and acute coronary syndromes|
|DB12578||Lexaptepid Pegol||Not Available|
|DB08894||Peginesatide||Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis |
|DB13200||Lipegfilgrastim||Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441]. |
|DB12258||Abicipar Pegol||Not Available|
|DB14712||Elapegademase||Elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.[L4654] This condition was previously treated by the use of pegamedase bovine as part of an enzyme replacement therapy.[L4655]
ADA-SCID is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme. The patients suffering from this disease often present a compromised immune system. This condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infections.[L4656]|
|DB05321||PEG-uricase||Investigated for use/treatment in hyperuricemia.|
|DB09329||Antihemophilic Factor (Recombinant), PEGylated||For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064].
This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].|
|DB11661||Eptacog alfa pegol (activated)||Not Available|
|DB00061||Pegademase||For treatment of adenosine deaminase deficiency|
|DB09122||Peginterferon beta-1a||For the treatment of patients with relapsing forms of multiple sclerosis.|
|DB06022||GlycoPEG-GCSF||Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.|
|DB04895||Pegaptanib||For the treatment of neovascular (wet) age-related macular degeneration.|
|DB09208||Pegloticase||For the treatment of chronic gout in adult patients refractory to conventional therapy.|
|DB08904||Certolizumab pegol||Certolizumab pegol has been approved for several different conditions listed below:
- Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy.
- Treatment of adult patients with moderate to severely active rheumatoid arthritis.
- Treatment of adult patients with active psoriatic arthritis.
- Treatment of adult patients with active ankylosing spondylitis.
- Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label]
- Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819]
In Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825]
Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660] |
|DB06293||Pegnivacogin||Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.|
|DB11707||Olaptesed Pegol||Not Available|
|DB06325||Pegpleranib||Investigated for use/treatment in macular degeneration and eye disorders/infections.|
|DB03394||Heptaethylene glycol||Not Available|
|DB11225||Peg-100 stearate||Not Available|
|DB06611||Pegsunercept||Investigated for use/treatment in rheumatoid arthritis.|
|DB14700||Damoctocog alfa pegol||Indicated for use in previously treated adults and adolescents (12 years of age and above) with hemophilia A (congenital Factor VIII deficiency) for:
On-demand treatment and control of bleeding episodes [FDA label], perioperative management of bleeding [FDA label], and routine prophylaxis to reduce the frequency of bleeding episodes [FDA label].|
|DB11567||Insulin peglispro||Not Available|
|DB12839||Pegvaliase||Pegvaliase is indicated for the management of phenylketonuria (PKU) in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. |
|DB14142||Methoxy PEG-12 retinamide||Not Available|
|DB09107||Methoxy polyethylene glycol-epoetin beta||For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.|
|DB12814||Cepeginterferon alfa-2B||Not Available|
|DB13933||Nonacog beta pegol||Nonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]|
|DB00059||Pegaspargase||For treatment of acute lymphoblastic leukemia|
|DB06811||Polidocanol||Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. |
|DB00008||Peginterferon alfa-2a||Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].|
|DB05860||Peginterferon alfacon-1||Investigated for use/treatment in hepatitis (viral, C).|
|DB00022||Peginterferon alfa-2b||Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|DB01839||Propylene glycol||Not Available|
|DB09287||Polyethylene glycol||Used to treat and prevent constipation.|
|DB11077||Polyethylene glycol 400||PEG-400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye, and
for protection against further irritation and desiccation [L1795], [L1796], [L1797].|
|DB00082||Pegvisomant||Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.|
|DB00019||Pegfilgrastim||Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.|